Sacit Nuri Gorgel1, Osman Kose1, Esra Meltem Koc2, Erhan Ates3, Yigit Akin4, Yuksel Yilmaz1. 1. Department of Urology, Izmir Katip Celebi University School of Medicine, 35640, Izmir, Turkey. 2. Department of Family Medicine, Izmir Katip Celebi University School of Medicine, Izmir, Turkey. 3. Department of Urology, Adnan Menderes University School of Medicine, Aydin, Turkey. 4. Department of Urology, Izmir Katip Celebi University School of Medicine, 35640, Izmir, Turkey. yigitakin@yahoo.com.
Abstract
PURPOSES: We aimed to evaluate prognostic significance of preoperatively assessed aspartate aminotransaminase (AST)/alanine aminotransferase (ALT) (De Ritis) ratio on survival in bladder cancer (BC) patients underwent radical cystectomy (RC). METHODS: We, respectively, analysed clinical and pathological data of 153 patients who underwent RC for BC between February 2006 and December 2016 at a tertiary level hospital. The potential prognostic value of De Ritis ratio was assessed by using ROC curve analysis. The effect of the De Ritis ratio was analysed by the Kaplan-Meier method and Cox regression hazard models for patients' disease-specific survival (DSS) and overall survival (OAS). RESULTS: We had 149 BC patients, in total. Mean age was 61.65 ± 9.13 years. One hundred and thirty-nine (93.3%) of the patients were men. According to ROC analysis, optimal threshold of De Ritis ratio for DSS was 1.30. In Kaplan-Meier analyses, the high De Ritis ratio group showed worse progression in DSS and OAS (all parameters, p < 0.001). On Cox regression models of clinical and pathological parameters to predict DSS, De Ritis ratio (HR 5.79, 95% CI 2.25-15.13), pathological T stage (HR 15.89, 95% CI 3.92-64.33, in all p < 0.001); and to predict OAS, De Ritis ratio (HR 2.61, 95% CI 1.49-4.56; p < 0.001), pathological T stage (HR 5.42, 95% CI 2.63-11.64; p < 0.001) and age (HR 1.05, 95% CI 1.02-1.08; p = 0.001) were determined as independent prognostic factors. CONCLUSIONS: Preoperative elevated De Ritis ratio could be an independent prognostic factor in BC patients underwent RC. Our results should be confirmed by large and properly designed prospective, randomized trials.
PURPOSES: We aimed to evaluate prognostic significance of preoperatively assessed aspartate aminotransaminase (AST)/alanine aminotransferase (ALT) (De Ritis) ratio on survival in bladder cancer (BC) patients underwent radical cystectomy (RC). METHODS: We, respectively, analysed clinical and pathological data of 153 patients who underwent RC for BC between February 2006 and December 2016 at a tertiary level hospital. The potential prognostic value of De Ritis ratio was assessed by using ROC curve analysis. The effect of the De Ritis ratio was analysed by the Kaplan-Meier method and Cox regression hazard models for patients' disease-specific survival (DSS) and overall survival (OAS). RESULTS: We had 149 BC patients, in total. Mean age was 61.65 ± 9.13 years. One hundred and thirty-nine (93.3%) of the patients were men. According to ROC analysis, optimal threshold of De Ritis ratio for DSS was 1.30. In Kaplan-Meier analyses, the high De Ritis ratio group showed worse progression in DSS and OAS (all parameters, p < 0.001). On Cox regression models of clinical and pathological parameters to predict DSS, De Ritis ratio (HR 5.79, 95% CI 2.25-15.13), pathological T stage (HR 15.89, 95% CI 3.92-64.33, in all p < 0.001); and to predict OAS, De Ritis ratio (HR 2.61, 95% CI 1.49-4.56; p < 0.001), pathological T stage (HR 5.42, 95% CI 2.63-11.64; p < 0.001) and age (HR 1.05, 95% CI 1.02-1.08; p = 0.001) were determined as independent prognostic factors. CONCLUSIONS: Preoperative elevated De Ritis ratio could be an independent prognostic factor in BC patients underwent RC. Our results should be confirmed by large and properly designed prospective, randomized trials.
Authors: M May; C Protzel; M W Vetterlein; M Gierth; J Noldus; A Karl; T Grimm; B Wullich; M O Grimm; P Nuhn; P J Bastian; J Roigas; B Hadaschik; C Gilfrich; M Burger; M Fisch; S Brookman-May; A Aziz; O W Hakenberg Journal: Int Urol Nephrol Date: 2016-11-28 Impact factor: 2.370
Authors: Chin-Chen Pan; Yen-Hwa Chang; Kuang-Kuo Chen; Hui-Jung Yu; Chih-Hao Sun; Donald M T Ho Journal: Am J Clin Pathol Date: 2010-05 Impact factor: 2.493
Authors: Maximilian Burger; James W F Catto; Guido Dalbagni; H Barton Grossman; Harry Herr; Pierre Karakiewicz; Wassim Kassouf; Lambertus A Kiemeney; Carlo La Vecchia; Shahrokh Shariat; Yair Lotan Journal: Eur Urol Date: 2012-07-25 Impact factor: 20.096
Authors: Yang Hyun Cho; Jun Eul Hwang; Ho Seok Chung; Myung Soo Kim; Eu Chang Hwang; Seung Il Jung; Taek Won Kang; Dong Deuk Kwon; Seock Hwan Choi; Hyun Tae Kim; Tae-Hwan Kim; Tae Gyun Kwon; Joon Hwa Noh; Myung Ki Kim; Chul-Sung Kim; Sung Gu Kang; Seok Ho Kang; Jun Cheon; Chan Ho Lee; Ja Yoon Ku; Hong Koo Ha; Bum Sik Tae; Chang Wook Jeong; Ja Hyeon Ku; Cheol Kwak; Hyeon Hoe Kim Journal: Int Urol Nephrol Date: 2017-05-08 Impact factor: 2.370
Authors: Jakob Michael Riedl; Florian Posch; Gerald Prager; Wolfgang Eisterer; Leopold Oehler; Thamer Sliwa; Klaus Wilthoner; Andreas Petzer; Petra Pichler; Eva Hubmann; Thomas Winder; Sonja Burgstaller; Markus Korger; Johannes Andel; Richard Greil; Hans-Joerg Neumann; Martin Pecherstorfer; Kathrin Philipp-Abbrederis; Angela Djanani; Birgit Gruenberger; Friedrich Laengle; Ewald Wöll; Armin Gerger Journal: Ther Adv Med Oncol Date: 2020-04-10 Impact factor: 8.168